344P - TERT as a prognostic factor for gliomas progression-free survival (PFS)
Date | 09 October 2016 |
Event | ESMO 2016 Congress |
Session | Poster display |
Topics | Central Nervous System Malignancies |
Presenter | Maria Pilar Solis Hernandez |
Citation | Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367 |
Authors |
M.P. Solis Hernandez1, L. Faez1, D. Cantero2, A. Hernandez Lain2, P. Sanchez Gomez2, Y. Ruano2, M.D.M. Galera3, J.M. Sepúlveda Sánchez3
|
Abstract
Background
High frequencies of TERT promoter mutations have been described in gliomas. This underlies telomere maintenance upregulating telomerases. The mutation rate is higher in glioblastomas (GBM).
Methods
Observational and retrospective analysis of 100 patients with different histological types of gliomas. TERT mutations were determined by RT-PCR in brain tumor samples obtained from paraffin-embedded tissue. Survival analysis was performed with Kaplan-Meier curves compared by Log-Rank test.
Results
There were included 52% GBM, oligodendrogliomas (OO) 12% and astrocytomas (AA) 29% each, and oligoastrocytomas (OA) 7%. The highest rate of TERT mutation was achieved in the OO group (66.7%) followed by GBM (55.8%) and AA (27.6%). From the 46% patients with TERT mutation: GBM 63%, OO and AA each 17.4%. Median relapse/progression free survival was 37, 33 and 7 months for AA, OO, OA and GBM respectively if wild type TERT, while if mutated 14, 20 and 8 months. TERT and ATRX seem to be mutually exclusive as there were only 2% coincidences.
Wild type TERT | Mutated TERT | |||
---|---|---|---|---|
Median PFS | Range | Median PFS | Range | |
Astrocytoma | 37.6 | 124 | 14.2 | 120 |
Glioblastoma | 7.1 | 37 | 8.8 | 42 |
Oligoastrocytoma | 19.3 | 73 | 82.7 | 0 |
Oligodendroglioma | 33.1 | 34 | 20.7 | 98 |
Conclusions
TERT mutations are determinant prognostic factors in glioma biology of both high and low grade.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitario 12 de Octubre: Multidisciplinar Neurooncology Unit
Funding
Hospital Universitario 12 de Octubre: Multidisciplinar Neurooncology Unit
Disclosure
All authors have declared no conflicts of interest.